Microbial therapeutics: New opportunities for drug delivery
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of admi...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Rockefeller University Press
2020
|
| Online Access: | https://hdl.handle.net/1721.1/126020 |
| _version_ | 1826193982420418560 |
|---|---|
| author | Jimenez, Miguel Langer, Robert S Traverso, Carlo Giovanni |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Jimenez, Miguel Langer, Robert S Traverso, Carlo Giovanni |
| author_sort | Jimenez, Miguel |
| collection | MIT |
| description | With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics. |
| first_indexed | 2024-09-23T09:48:44Z |
| format | Article |
| id | mit-1721.1/126020 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T09:48:44Z |
| publishDate | 2020 |
| publisher | Rockefeller University Press |
| record_format | dspace |
| spelling | mit-1721.1/1260202022-09-26T13:51:31Z Microbial therapeutics: New opportunities for drug delivery Jimenez, Miguel Langer, Robert S Traverso, Carlo Giovanni Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Department of Mechanical Engineering Koch Institute for Integrative Cancer Research at MIT With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics. 2020-06-29T20:34:21Z 2020-06-29T20:34:21Z 2019-04 2019-12-10T13:14:40Z Article http://purl.org/eprint/type/JournalArticle 0022-1007 1540-9538 https://hdl.handle.net/1721.1/126020 Jimenez, Miguel et al. "Microbial therapeutics: New opportunities for drug delivery." Journal of Experimental Medicine 216, 5 (April 2019): 1005–1009 © 2019 MIT en http://dx.doi.org/10.1084/jem.20190609 Journal of Experimental Medicine Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Rockefeller University Press Journal of Experimental Medicine (JEM) |
| spellingShingle | Jimenez, Miguel Langer, Robert S Traverso, Carlo Giovanni Microbial therapeutics: New opportunities for drug delivery |
| title | Microbial therapeutics: New opportunities for drug delivery |
| title_full | Microbial therapeutics: New opportunities for drug delivery |
| title_fullStr | Microbial therapeutics: New opportunities for drug delivery |
| title_full_unstemmed | Microbial therapeutics: New opportunities for drug delivery |
| title_short | Microbial therapeutics: New opportunities for drug delivery |
| title_sort | microbial therapeutics new opportunities for drug delivery |
| url | https://hdl.handle.net/1721.1/126020 |
| work_keys_str_mv | AT jimenezmiguel microbialtherapeuticsnewopportunitiesfordrugdelivery AT langerroberts microbialtherapeuticsnewopportunitiesfordrugdelivery AT traversocarlogiovanni microbialtherapeuticsnewopportunitiesfordrugdelivery |